Tobias Hofving
-
177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90
inhibition
Tobias Hofving, Viktor Sandblom, Yvonne Arvidsson, Emman Shubbar, Gülay Altiparmak, John Swanpalmer, Bilal Almobarak, Anna-Karin Elf, Viktor Johanson, Erik Elias, Erik Kristiansson, Eva Forssell-Aronsson, Ola Nilsson
Endocrine-Related Cancer - 2019-01-01 -
H-STS, L-STS and KRJ-I are not authentic GEPNET cell
lines.
Tobias Hofving, Joakim Karlsson, Ola Nilsson, Jonas A Nilsson
Nature genetics - 2019-01-01 -
Small intestinal neuroendocrine tumours - Disease models, tumour development, and
remedy
Tobias Hofving
- 2019-01-01 -
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell
lines
Tobias Hofving, Yvonne Arvidsson, Bilal Almobarak, Linda Inge, R. Pfragner, Marta Persson, Göran Stenman, Erik Kristiansson, Viktor Johanson, Ola Nilsson
Endocrine-Related Cancer - 2018-01-01 -
NAMPT inhibitor GMX1778 enhances the efficacy of 177Lu-DOTATATE treatment of neuroendocrine
tumors.
Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson, Viktor Johanson
Journal of Nuclear Medicine - 2017-01-01 -
Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic
targets.
Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson
Modern Pathology - 2016-01-01 -
Extreme female promiscuity in a non-social invertebrate
species
Marina Panova, Johan Boström, Tobias Hofving, Therese Areskoug, Anders Eriksson, Bernhard Mehlig, Tuuli Mäkinen, Carl André, Kerstin Johannesson
PLoS ONE - 2010-01-01